United States Patent 11,732,024 Claims and US Patent Landscape: Scope, Validity Risks, and Generic-Entry Exposure
US Patent 11,732,024 presents a claim set that defines enforceable boundaries for a specific pharmaceutical invention in the US. The practical value for R&D, licensing, and litigation depends on three things: (1) what the independent claims require, (2) whether the specification’s embodiments support the claim scope, and (3) how the claim scope overlaps with earlier patents and later competing “design-around” variants.
Critical limitation: no patent publication details (title/abstract), claim text, inventors/assignees, priority data, or the USPTO application publication number were provided. Without those, a complete and accurate claim-by-claim analysis and landscape mapping cannot be produced.
What is in the claims of US Patent 11,732,024 and what do they cover?
Answer (requires claim text):
A claim chart style breakdown requires the actual independent and dependent claim language from US 11,732,024, including:
- the independent claim elements (composition, method, use, device, process, or kit)
- any required parameters (ranges, temperature/time, pH, particle size, dissolution, dosing regimen)
- any required subsets (specific substituents, molecular structures, polymorph identifiers, specific excipients, manufacturing steps, or biological markers)
- any functional limitations (“effective to,” “capable of,” “reducing,” “increasing”) that drive novelty and non-obviousness risk
Without the claim set text, any mapping would be speculative.
Which claim types are most enforceable: composition, method-of-use, or manufacturing process?
Answer (requires claim text):
US patents can be attacked and enforced differently depending on whether the key claims are:
- composition claims: typically strong against formulation-copying; vulnerable to prior art compositions with overlapping ranges
- method-of-use claims: often harder to prove in litigation absent documentation, but can block approved indications or labeling-linked practice
- manufacturing/process claims: can be powerful against contract manufacturers; often face enablement and indefiniteness attacks tied to spec support
- kit/device/system claims: enforceability depends on actual commercial packaging and fulfillment practices
A proper assessment needs the claim categories used in US 11,732,024.
How broad are the independent claims in US Patent 11,732,024?
Answer (requires claim text):
Breadth is determined by:
- how many optional vs mandatory features exist in the claim grammar
- whether the claims are structural (precise chemical structures) or parameter/functional
- whether the claim uses open-ended language (“comprising”) or closed language (“consisting of”)
- whether numerical ranges are anchored to the examples or are floating
What claim construction issues commonly decide validity and infringement?
Key construction levers include:
- “effective amount” and other functional phrases
- defined terms versus ordinary meaning disputes
- range interpretation (endpoint inclusion; sub-range support; interpolation arguments)
- product-by-process limitations (if process is recited to define a product)
A construction-driven analysis requires the exact wording.
What prior art most threatens US 11,732,024’s novelty under 35 USC 102?
Answer (requires identifying the invention domain):
A novelty threat analysis requires:
- the drug/invention identity (active ingredient or technology)
- claim scope
- priority date and earliest filing
- the relevant publication corpus
Without title/abstract and claim text, a correct prior-art set cannot be assembled, and any list of references would lack integrity.
Which earlier US patents or PCT publications typically overlap?
Overlap frequently comes from:
- earlier polymorph/crystal patents
- earlier formulation patents (same actives, same excipients, similar ranges)
- earlier methods of treatment (same indication, dosing regimen, endpoints)
- earlier manufacturing steps (same process controls, drying/granulation parameters)
Identifying which category applies depends entirely on the claim elements.
Is US Patent 11,732,024 vulnerable under 35 USC 103 obviousness?
Answer (requires claim text + priority + spec):
Obviousness analysis requires:
- mapping claim elements to disclosures in the best prior art references
- identifying the missing feature(s) and whether they are the predictable result of routine optimization
- evaluating whether the specification supports the claimed invention as more than an obvious variation
What does “motivation to combine” look like for formulation vs method claims?
- For formulations, obviousness often turns on whether prior art teaches the same components and whether the claimed improvement is unexpected (stability, bioavailability, dissolution)
- For method-of-use, it turns on whether prior art teaches the regimen, biomarkers, and patient population
- For process, it turns on whether process steps are conventional and whether the claimed criticality is demonstrated
This cannot be assessed without the actual claim and disclosed examples.
What indefiniteness and enablement risks exist for US 11,732,024?
Answer (requires specification details and claim wording):
Common post-grant risk patterns include:
- indefiniteness from undefined functional limitations
- enablement failures when claimed breadth exceeds what examples support
- lack of clarity around intermediates, polymorph definitions, particle-size/PSD metrics, or analytical methods
A true critical analysis requires the specification’s enablement support and the claim’s definitional scope.
How strong is the patent estate around US 11,732,024 (continuations, divisionals, and family coverage)?
Answer (requires family data):
A landscape-quality “strength” view normally reports:
- continuation/divisional chain count
- related filings in the US and other jurisdictions
- whether later filings broaden or narrow the claim set
- whether the same priority family contains overlapping subject matter patents
This requires bibliographic data and at least the application publication number.
What patents does US 11,732,024 cite, and how does that affect validity and licensing leverage?
Answer (requires cited-reference list):
A cited-reference list helps determine:
- whether the examiner allowed claims over known art
- which references the applicant distinguished
- whether those distinctions are likely to be rebutted later by new combinations
Without the list, no credible assessment can be made.
Is US 11,732,024 asserted in litigation, PTAB, or ITC proceedings?
Answer (requires litigation database lookup):
A litigation exposure section normally reports:
- case captions and courts
- asserted claims
- accused products/processes
- status (dismissed, stayed, trial, Markman outcome, settlement date)
No such data was provided.
What generic entry risks exist if US 11,732,024 is a drug-formulation or method-of-use patent?
Answer (requires the drug/regulatory link):
Generic entry timing depends on:
- whether the patent is listed in the FDA Orange Book for an NDC
- whether it is tied to an approved indication (method-of-use patents)
- whether it is tied to manufacturing (often harder to predict for generic practice)
- whether the generic can launch using a non-infringing formulation or different regimen
No FDA regulatory linkage or Orange Book data was provided.
Orange Book status: is US 11,732,024 listed, and for which NDC/label?
Answer (requires Orange Book/NDC mapping):
A correct answer needs:
- Orange Book patent number listing
- drug product NDC(s)
- patent type code (composition, method, device)
- expiration and listed use codes
How does US 11,732,024 compare with other patents covering the same active ingredient or delivery system?
Answer (requires invention identity and family):
A defensible comparison requires:
- identifying close patents (same active, same indication, same dosage/formulation class)
- comparing claim scope and parameter ranges
- assessing whether US 11,732,024 is a “core” blocking patent or a narrower improvement patent
Without the invention identity, no valid comparison can be created.
Commercial exposure: what revenues and competitive products hinge on US 11,732,024’s remaining term?
Answer (requires drug identity):
To quantify exposure, a landscape analysis typically includes:
- remaining patent term and any PTA/PTE
- exclusivity blocks (NDAs and 180-day exclusivity triggers)
- competitor product list (brands and authorized generics/biosimilars where applicable)
- likely generic launch scenarios by pathway (ANDA 505(b)(2) or 505(j))
No commercial or term data was provided.
Key Takeaways
No complete and accurate analysis can be produced without the patent’s claim text and bibliographic identity (title/abstract, assignee, priority/application publication). A “comprehensive and critical” landscape requires those inputs to avoid speculative or incorrect conclusions about novelty, obviousness, enforceable scope, and generic entry risk.
FAQs
- What claim elements typically drive infringement for pharmaceutical patents like US 11,732,024?
- How do courts construe functional limitations in composition or method claims?
- What is the most common invalidity pathway: 102 novelty, 103 obviousness, or 112 enablement/indefiniteness?
- How can a generic design around a formulation patent while still meeting bioequivalence?
- What does Orange Book patent listing reveal about enforcement likelihood?
References
(No sources cited because no patent text, bibliographic identifiers, or regulatory linkage data were provided.)
